MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose C...( MONMOUTH JUNCTION N.J. Aug. 6 /- ...),Health

MONMOUTH JUNCTION, N.J., Aug. 6 /PRNewswire/ -- MicroDose Technologies, Inc., a privately held drug delivery and specialty pharmaceuticals company, today announces top line results from a glucose clamp study of the QDose inhaled insulin product. MicroDose, through its joint venture with Vectura Group plc, QDose Limited, has developed a highly efficient, rapid acting, insulin inhaler, based upon MicroDose's proprietary electronic inhaler technology and Vectura's dry powder insulin formulation. The QDose inhaled insulin product offers dose titration capability over a broad range of dose strengths, in a single inhalation. The inhaler also provides active dose feedbacks to the patient in an easy to use, pocket-sized device.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070803/NYF045LOGO )

The study employed the widely used and validated glucose clamp technique, and results demonstrated that:

-- The inhaled insulin formulation was safe and effective

-- Peak levels of insulin activity were achieved more quickly following

the inhaled insulin than those from the subcutaneous insulin injection

-- Relative bioavailability of inhaled insulin was approximately 18%

during the 3 hour period following dosing; higher than the published

values for the currently marketed inhalation product

-- Administration of the same total dose of inhaled insulin from either a

single blister or two "half strength" blisters led to equivalent

activity; an advantage over the currently marketed inhalation product

The study was a randomized, crossover, open-label glucose clamp study, designed to confirm the high relative bioavailability of the QDose insulin formulation previously observed, and to demonstrate the product's dose titration capability. The results confirmed the faster onset of action seen with the QDose inhaled formu
'/>"/>

SOURCE MicroDose Technologies, Inc. Copyright©2007 PR Newswire.

0 GOOD